Merck Slashes Terns Pharmaceuticals Bid by $1 Billion Following Clinical Data Review
First Detected: Apr 16, 2026, 10:18 PM
Last Update: 5 months ago
5 articles·4 stories
Event Summary
On April 16, Merck reduced its acquisition offer for Terns Pharmaceuticals by $1 billion to a total of $6.7 billion. The per-share offer was lowered from $61 to $53 following a review of cancer drug trial data.
